/
We are a clinical-stage, precision medicine pharmaceutical company focused on developing novel anti-cancer therapeutics for patients with high unmet medical need. We were founded on the innovation of our novel Drug Response Predictor (DRP ) platform.
The business is unprofitable at the operating level (-3939.06% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Negative free cash flow of -$15M. The business is consuming cash, not generating it.
Profitability & Returns
Revenue (FY)
$320K
Net Income (TTM)
-$11M
▲ +54.2% YoY
Op. Margin
-3939.06%
ROIC
-63.49%
▲ +180.7pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$17M
▲ +16.0% YoY
Op. Cash Flow (TTM)
-$17M
▲ +14.6% YoY
Net Debt
$268K
Cash & Equiv.
$20M
Continue Research